Dan Peer

Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is the Director of a national nanomedicine initiative project. He is also the Director of Leona M. and Harry B. Helmsley Nanotechnology Research Fund and the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals.

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in Cancer and inflammation.

Prof. Peer and his team have done innovative and groundbreaking work in cancer, mostly in brain tumors (Glioblastoma), Ovarian Cancer, and a set of blood cancers (Mantle Cell Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia).

His work is published in premier scientific journals and he is the editor and author of several books in the field of nanomedicine. In addition, he is an associate editor of Journal of Controlled Release, and a member of the editorial boards of numerous journals including Cancer Letters and ACS Bioconjugate Chemistry.  He has received more than 30 awards; among them, he was recognized by the Kenneth Rainin Foundation by their Innovator (2010) and Breakthrough (2011 – 2013) Awards for his pioneering work in inflammatory bowel diseases and by the AAAS and the Untold news breakthrough Award for his development of the Gagomers platform for cancer targeted drug delivery. In 2017, he received the  2017 Nanos Award for major contribution to the field of clinical nanomedicine in CLINAM 10th, Basal, Switzerland.

Prof. Peer has more than 120 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, five spin-off companies were generated Leuko Biosciences, Quiet Therapeutics, SEPL Pharma, NeoCure Pharma and ART Bioscience aiming to bring personalized medicine into clinical practice.

Prof. Peer is a past Present of the Israeli Chapter of the Controlled Release Society, and a Member of the Israel Young Academy of Sciences.